{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:41:41Z","timestamp":1793392901437,"version":"4.5.0"},"reference-count":268,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-021-00307-9","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T04:29:40Z","timestamp":1633580980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Histiocytic disorders"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-6263","authenticated-orcid":false,"given":"Kenneth L.","family":"McClain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-2087","authenticated-orcid":false,"given":"Camille","family":"Bigenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-6422","authenticated-orcid":false,"given":"Jennifer","family":"Picarsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina B.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"307_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-C","volume":"29","author":"BE Favara","year":"1997","unstructured":"Favara, B. E. et al. Contemporary classification of histiocytic disorders. Med. Pediatr. Oncol. 29, 157\u2013166 (1997).","journal-title":"Med. Pediatr. Oncol."},{"key":"307_CR2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile, J. F. et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127, 2672\u20132681 (2016).","journal-title":"Blood"},{"key":"307_CR3","first-page":"383","volume":"15","author":"L Aschoff","year":"1913","unstructured":"Aschoff, L. & Kiyono, K. Frage der grossen Mononulearn. Folia Haematol. 15, 383\u2013390 (1913).","journal-title":"Folia Haematol."},{"key":"307_CR4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","volume":"137","author":"RM Steinman","year":"1973","unstructured":"Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142\u20131162 (1973).","journal-title":"J. Exp. Med."},{"key":"307_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1084\/jem.139.2.380","volume":"139","author":"RM Steinman","year":"1974","unstructured":"Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J. Exp. Med. 139, 380\u2013397 (1974).","journal-title":"J. Exp. Med."},{"key":"307_CR6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"307_CR7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41591-021-01304-x","volume":"27","author":"C Bigenwald","year":"2021","unstructured":"Bigenwald, C., Chakraborty, R. & Chen, S. T. BRAFV600E-induced senescence in hematopoietic progenitors drives Langerhans cell histiocytosis pathophysiology. Nat. Med. 27, 851\u2013861 (2021).","journal-title":"Nat. Med."},{"key":"307_CR8","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.4049\/jimmunol.0902336","volume":"184","author":"CE Allen","year":"2010","unstructured":"Allen, C. E. et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J. Immunol. 184, 4557\u20134567 (2010).","journal-title":"J. Immunol."},{"key":"307_CR9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","volume":"379","author":"CE Allen","year":"2018","unstructured":"Allen, C. E., Merad, M. & McClain, K. L. Langerhans-cell histiocytosis. N. Engl. J. Med. 379, 856\u2013868 (2018).","journal-title":"N. Engl. J. Med."},{"key":"307_CR10","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H. & McClain, K. L. How I treat hemophagocytic lymphohistiocytosis. Blood 118, 4041\u20134052 (2011).","journal-title":"Blood"},{"key":"307_CR11","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","volume":"111","author":"H Gadner","year":"2008","unstructured":"Gadner, H. et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 111, 2556\u20132562 (2008).","journal-title":"Blood"},{"key":"307_CR12","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.31348","volume":"124","author":"KL McClain","year":"2018","unstructured":"McClain, K. L. et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124, 2607\u20132620 (2018).","journal-title":"Cancer"},{"issue":"Suppl. 16","key":"307_CR13","doi-asserted-by":"crossref","first-page":"P3.266","DOI":"10.1212\/WNL.86.16_supplement.P3.266","volume":"86","author":"EA Yeh","year":"2016","unstructured":"Yeh, E. A. et al. Clinical and radiographic improvement of neurodegenerative Langerhans cell histiocytosis (ND-LCH) following dabrafenib [abstract]. Neurology 86 (Suppl. 16), P3.266 (2016).","journal-title":"Neurology"},{"key":"307_CR14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche, J. et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J. Clin. Oncol. 33, 411\u2013418 (2015).","journal-title":"J. Clin. Oncol."},{"key":"307_CR15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","volume":"41","author":"B Hervier","year":"2012","unstructured":"Hervier, B. et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-\u03b1. Semin. Arthritis Rheum. 41, 907\u2013913 (2012).","journal-title":"Semin. Arthritis Rheum."},{"key":"307_CR16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.25404","volume":"62","author":"KB Ribeiro","year":"2015","unstructured":"Ribeiro, K. B., Degar, B., Antoneli, C. B., Rollins, B. & Rodriguez-Galindo, C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr. Blood Cancer 62, 982\u2013987 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.21498","volume":"51","author":"A Guyot-Goubin","year":"2008","unstructured":"Guyot-Goubin, A. et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr. Blood Cancer 51, 71\u201375 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/pbc.20884","volume":"48","author":"RD Alston","year":"2007","unstructured":"Alston, R. D. et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr. Blood Cancer 48, 555\u2013560 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/pbc.21504","volume":"51","author":"H Stalemark","year":"2008","unstructured":"Stalemark, H. et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr. Blood Cancer 51, 76\u201381 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR20","unstructured":"Weiss, L. M. & Facchetti, F. in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) 470\u2013472 (IARC, 2017)."},{"key":"307_CR21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3476(97)80021-2","volume":"130","author":"S Bhatia","year":"1997","unstructured":"Bhatia, S. et al. Epidemiologic study of Langerhans cell histiocytosis in children. J. Pediatr. 130, 774\u2013784 (1997).","journal-title":"J. Pediatr."},{"key":"307_CR22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/pbc.24136","volume":"59","author":"R Venkatramani","year":"2012","unstructured":"Venkatramani, R., Rosenberg, S., Indramohan, G., Jeng, M. & Jubran, R. An exploratory epidemiological study of Langerhans cell histiocytosis. Pediatr. Blood Cancer 59, 1324\u20131326 (2012).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.annepidem.2018.04.005","volume":"28","author":"EC Peckham-Gregory","year":"2018","unstructured":"Peckham-Gregory, E. C., McClain, K. L., Allen, C. E., Scheurer, M. E. & Lupo, P. J. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann. Epidemiol. 28, 521\u2013528 (2018).","journal-title":"Ann. Epidemiol."},{"key":"307_CR24","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2017-08-800565","volume":"130","author":"EC Peckham-Gregory","year":"2017","unstructured":"Peckham-Gregory, E. C. et al. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood 130, 2229\u20132232 (2017).","journal-title":"Blood"},{"key":"307_CR25","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJM200006293422607","volume":"342","author":"R Vassallo","year":"2000","unstructured":"Vassallo, R., Ryu, J. H., Colby, T. V., Hartman, T. & Limper, A. H. Pulmonary Langerhans\u2019-cell histiocytosis. N. Engl. J. Med. 342, 1969\u20131978 (2000).","journal-title":"N. Engl. J. Med."},{"key":"307_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.14818","volume":"182","author":"G Goyal","year":"2018","unstructured":"Goyal, G. et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br. J. Haematol. 182, 579\u2013581 (2018).","journal-title":"Br. J. Haematol."},{"key":"307_CR27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MPH.0b013e3181b76827","volume":"31","author":"TA Tran","year":"2009","unstructured":"Tran, T. A. et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. J. Pediatr. Hematol. Oncol. 31, 782\u2013786 (2009).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"307_CR28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.2019002766","volume":"135","author":"J Haroche","year":"2020","unstructured":"Haroche, J., Cohen-Aubart, F. & Amoura, Z. Erdheim-Chester disease. Blood 135, 1311\u20131318 (2020).","journal-title":"Blood"},{"key":"307_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.pas.0000147395.01229.06","volume":"29","author":"D Janssen","year":"2005","unstructured":"Janssen, D. & Harms, D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the Kiel Pediatric Tumor Registry. Am. J. Surg. Pathol. 29, 21\u201328 (2005).","journal-title":"Am. J. Surg. Pathol."},{"key":"307_CR30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/pbc.20725","volume":"47","author":"H Isaacs Jr.","year":"2006","unstructured":"Isaacs, H. Jr. Fetal and neonatal histiocytoses. Pediatr. Blood Cancer 47, 123\u2013129 (2006).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.0736-8046.2004.21201.x","volume":"21","author":"S Cambiaghi","year":"2004","unstructured":"Cambiaghi, S., Restano, L. & Caputo, R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr. Dermatol. 21, 97\u2013101 (2004).","journal-title":"Pediatr. Dermatol."},{"key":"307_CR32","first-page":"1169","volume":"58","author":"P Destombes","year":"1965","unstructured":"Destombes, P. Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases) [French]. Bull. Soc. Pathol. Exot. Filiales. 58, 1169\u20131175 (1965).","journal-title":"Bull. Soc. Pathol. Exot. Filiales."},{"key":"307_CR33","first-page":"63","volume":"87","author":"J Rosai","year":"1969","unstructured":"Rosai, J. & Dorfman, R. F. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch. Pathol. 87, 63\u201370 (1969).","journal-title":"Arch. Pathol."},{"key":"307_CR34","first-page":"19","volume":"7","author":"E Foucar","year":"1990","unstructured":"Foucar, E., Rosai, J. & Dorfman, R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin. Diagn. Pathol. 7, 19\u201373 (1990).","journal-title":"Semin. Diagn. Pathol."},{"key":"307_CR35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/RCT.0000000000000983","volume":"44","author":"M Elshikh","year":"2020","unstructured":"Elshikh, M. et al. Disease characteristics, radiologic patterns, comorbid diseases, and ethnic differences in 32 patients with Rosai-Dorfman disease. J. Comput. Assist. Tomogr. 44, 450\u2013461 (2020).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"307_CR36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2133.2005.06917.x","volume":"154","author":"KH Wang","year":"2006","unstructured":"Wang, K. H. et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br. J. Dermatol. 154, 277\u2013286 (2006).","journal-title":"Br. J. Dermatol."},{"key":"307_CR37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","volume":"80","author":"JI Henter","year":"1991","unstructured":"Henter, J. I., Elinder, G., Soder, O. & Ost, A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand. 80, 428\u2013435 (1991).","journal-title":"Acta Paediatr. Scand."},{"key":"307_CR38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pbc.25308","volume":"62","author":"M Meeths","year":"2015","unstructured":"Meeths, M., Horne, A., Sabel, M., Bryceson, Y. T. & Henter, J. I. Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr. Blood Cancer 62, 346\u2013352 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","volume":"50","author":"CE Allen","year":"2008","unstructured":"Allen, C. E., Yu, X., Kozinetz, C. A. & McClain, K. L. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 50, 1227\u20131235 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pbc.22359","volume":"54","author":"JA Niece","year":"2010","unstructured":"Niece, J. A., Rogers, Z. R., Ahmad, N., Langevin, A. M. & McClain, K. L. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr. Blood Cancer 54, 424\u2013428 (2010).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1532\/IJH97.07012","volume":"86","author":"E Ishii","year":"2007","unstructured":"Ishii, E. et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int. J. Hematol. 86, 58\u201365 (2007).","journal-title":"Int. J. Hematol."},{"key":"307_CR42","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3389\/fimmu.2017.01902","volume":"8","author":"RA Marsh","year":"2017","unstructured":"Marsh, R. A. Epstein-Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 8, 1902 (2017).","journal-title":"Front Immunol."},{"key":"307_CR43","volume":"64","author":"XJ Xu","year":"2017","unstructured":"Xu, X. J. et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study. Pediatr. Blood Cancer 64, e26264 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01073-9","author":"O Shamriz","year":"2021","unstructured":"Shamriz, O. et al. T cell-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (HLH) occurs in non-Asians and is associated with a T cell activation state that is comparable to primary HLH. J. Clin. Immunol. https:\/\/doi.org\/10.1007\/s10875-021-01073-9 (2021).","journal-title":"J. Clin. Immunol."},{"key":"307_CR45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","volume":"132","author":"IK Chinn","year":"2018","unstructured":"Chinn, I. K. et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 132, 89\u2013100 (2018).","journal-title":"Blood"},{"key":"307_CR46","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","volume":"125","author":"AM Schram","year":"2015","unstructured":"Schram, A. M. & Berliner, N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125, 2908\u20132914 (2015).","journal-title":"Blood"},{"key":"307_CR47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals, M., Brito-Zeron, P., Lopez-Guillermo, A., Khamashta, M. A. & Bosch, X. Adult haemophagocytic syndrome. Lancet 383, 1503\u20131516 (2014).","journal-title":"Lancet"},{"key":"307_CR48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0889-8588(05)70514-1","volume":"12","author":"RJ Arceci","year":"1998","unstructured":"Arceci, R. J., Brenner, M. K. & Pritchard, J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol. Oncol. Clin. North Am. 12, 339\u2013357 (1998).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"307_CR49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM199407213310303","volume":"331","author":"CL Willman","year":"1994","unstructured":"Willman, C. L. et al. Langerhans\u2019-cell histiocytosis (histiocytosis X)\u2013a clonal proliferative disease. N. Engl. J. Med. 331, 154\u2013160 (1994).","journal-title":"N. Engl. J. Med."},{"key":"307_CR50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(94)91842-2","volume":"343","author":"RC Yu","year":"1994","unstructured":"Yu, R. C., Chu, C., Buluwela, L. & Chu, A. C. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343, 767\u2013768 (1994).","journal-title":"Lancet"},{"key":"307_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/gcc.20634","volume":"48","author":"CE Da Costa","year":"2009","unstructured":"Da Costa, C. E. et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer 48, 239\u2013249 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"307_CR52","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919\u20131923 (2010).","journal-title":"Blood"},{"key":"307_CR53","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar, A. A. & Poulikakos, P. I. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 13, 928\u2013942 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"307_CR54","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown, N. A. et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124, 1655\u20131658 (2014).","journal-title":"Blood"},{"key":"307_CR55","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1183\/13993003.01677-2015","volume":"47","author":"S Mourah","year":"2016","unstructured":"Mourah, S. et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur. Respir. J. 47, 1785\u20131796 (2016).","journal-title":"Eur. Respir. J."},{"key":"307_CR56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson, D. S. et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54, 361\u2013368 (2015).","journal-title":"Genes Chromosomes Cancer"},{"key":"307_CR57","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","volume":"128","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty, R. et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 128, 2533\u20132537 (2016).","journal-title":"Blood"},{"key":"307_CR58","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty, R. et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124, 3007\u20133015 (2014).","journal-title":"Blood"},{"key":"307_CR59","first-page":"365","volume":"18","author":"C Nezelof","year":"1973","unstructured":"Nezelof, C., Basset, F. & Rousseau, M. F. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine 18, 365\u2013371 (1973).","journal-title":"Biomedicine"},{"key":"307_CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/jid.1961.80","volume":"37","author":"MS Birbeck","year":"1961","unstructured":"Birbeck, M. S., Breathnach, A. S. & Everall, J. D. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J. Invest. Dermatol. 37, 51\u201364 (1961).","journal-title":"J. Invest. Dermatol."},{"key":"307_CR61","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nri2455","volume":"8","author":"M Merad","year":"2008","unstructured":"Merad, M., Ginhoux, F. & Collin, M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8, 935\u2013947 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"307_CR62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(00)80160-0","volume":"12","author":"J Valladeau","year":"2000","unstructured":"Valladeau, J. et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12, 71\u201381 (2000).","journal-title":"Immunity"},{"key":"307_CR63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres, M. L. et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J. Exp. Med. 211, 669\u2013683 (2014).","journal-title":"J. Exp. Med."},{"key":"307_CR64","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S Heritier","year":"2016","unstructured":"Heritier, S., Emile, J. F. & Barkaoui, M. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first line therapy. J. Clin. Oncol. 34, 3023\u20133030 (2016).","journal-title":"J. Clin. Oncol."},{"key":"307_CR65","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2016-12-757377","volume":"130","author":"BH Durham","year":"2017","unstructured":"Durham, B. H. et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem\/progenitor cells. Blood 130, 176\u2013180 (2017).","journal-title":"Blood"},{"key":"307_CR66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","volume":"130","author":"P Milne","year":"2017","unstructured":"Milne, P. et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 130, 167\u2013175 (2017).","journal-title":"Blood"},{"key":"307_CR67","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/2159-8290.CD-19-0138","volume":"9","author":"F Halbritter","year":"2019","unstructured":"Halbritter, F. et al. Epigenomics and single-cell sequencing define a developmental hierarchy in langerhans cell histiocytosis. Cancer Discov. 9, 1406\u20131421 (2019).","journal-title":"Cancer Discov."},{"key":"307_CR68","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","volume":"133","author":"OS Eckstein","year":"2019","unstructured":"Eckstein, O. S., Visser, J., Rodriguez-Galindo, C. & Allen, C. E. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood 133, 1691\u20131694 (2019).","journal-title":"Blood"},{"key":"307_CR69","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu, J. et al. Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study. J. Clin. Oncol. 37, 2857\u20132865 (2019).","journal-title":"J. Clin. Oncol."},{"key":"307_CR70","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood.2020005101","volume":"137","author":"AF Cohen","year":"2021","unstructured":"Cohen, A. F. et al. High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood 137, 485\u2013492 (2021).","journal-title":"Blood"},{"key":"307_CR71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/gcc.22252","volume":"54","author":"Y Yokokawa","year":"2015","unstructured":"Yokokawa, Y. et al. Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation. Genes Chromosomes Cancer 54, 409\u2013417 (2015).","journal-title":"Genes Chromosomes Cancer"},{"key":"307_CR72","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ajh.21044","volume":"83","author":"SJ Rodig","year":"2008","unstructured":"Rodig, S. J. et al. Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am. J. Hematol. 83, 116\u2013121 (2008).","journal-title":"Am. J. Hematol."},{"key":"307_CR73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.20161881","volume":"215","author":"B Hogstad","year":"2018","unstructured":"Hogstad, B. et al. RAF\/MEK\/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J. Exp. Med 215, 319\u2013336 (2018).","journal-title":"J. Exp. Med"},{"key":"307_CR74","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.2020005867","volume":"137","author":"A Sengal","year":"2021","unstructured":"Sengal, A. et al. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood 137, 1777\u20131791 (2021).","journal-title":"Blood"},{"key":"307_CR75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040253","volume":"4","author":"B Senechal","year":"2007","unstructured":"Senechal, B. et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS. Med. 4, e253 (2007).","journal-title":"PLoS. Med."},{"key":"307_CR76","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jpeds.2010.03.001","volume":"156","author":"N Grois","year":"2010","unstructured":"Grois, N. et al. Central nervous system disease in Langerhans cell histiocytosis. J. Pediatr. 156, 873\u2013881 (2010).","journal-title":"J. Pediatr."},{"key":"307_CR77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/brain\/awh403","volume":"128","author":"N Grois","year":"2005","unstructured":"Grois, N., Prayer, D., Prosch, H. & Lassmann, H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 128, 829\u2013838 (2005).","journal-title":"Brain"},{"key":"307_CR78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature23672","volume":"549","author":"E Mass","year":"2017","unstructured":"Mass, E. et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549, 389\u2013393 (2017).","journal-title":"Nature"},{"key":"307_CR79","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","volume":"18","author":"J Haroche","year":"2017","unstructured":"Haroche, J. et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 18, e113\u2013e125 (2017).","journal-title":"Lancet Oncol."},{"key":"307_CR80","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond, E. L. et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 6, 154\u2013165 (2016).","journal-title":"Cancer Discov."},{"key":"307_CR81","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","volume":"25","author":"BH Durham","year":"2019","unstructured":"Durham, B. H. et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat. Med 25, 1839\u20131842 (2019).","journal-title":"Nat. Med"},{"key":"307_CR82","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","volume":"124","author":"JF Emile","year":"2014","unstructured":"Emile, J. F. et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 124, 3016\u20133019 (2014).","journal-title":"Blood"},{"key":"307_CR83","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1182\/bloodadvances.2020001926","volume":"4","author":"A Rafiei","year":"2020","unstructured":"Rafiei, A. et al. BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. Blood Adv. 4, 4912\u20134917 (2020).","journal-title":"Blood Adv."},{"key":"307_CR84","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25055","volume":"93","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart, F. et al. Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. Am. J. Hematol. 93, E114\u2013E117 (2018).","journal-title":"Am. J. Hematol."},{"key":"307_CR85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40478-019-0811-6","volume":"7","author":"J Picarsic","year":"2019","unstructured":"Picarsic, J. et al. BRAF V600E mutation in juvenile xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol. Commun. 7, 168 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"307_CR86","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.0736-8046.2004.21219.x","volume":"21","author":"WH Burgdorf","year":"2004","unstructured":"Burgdorf, W. H. & Zelger, B. JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr. Dermatol. 21, 174\u2013176 (2004).","journal-title":"Pediatr. Dermatol."},{"key":"307_CR87","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archderm.1995.01690200040007","volume":"131","author":"A Zvulunov","year":"1995","unstructured":"Zvulunov, A., Barak, Y. & Metzker, A. Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis. Arch. Dermatol. 131, 904\u2013908 (1995).","journal-title":"Arch. Dermatol."},{"key":"307_CR88","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41379-018-0168-6","volume":"32","author":"KTE Chang","year":"2019","unstructured":"Chang, K. T. E. et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod. Pathol. 32, 598\u2013608 (2019).","journal-title":"Mod. Pathol."},{"key":"307_CR89","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","volume":"30","author":"S Garces","year":"2017","unstructured":"Garces, S. et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod. Pathol. 30, 1367\u20131377 (2017).","journal-title":"Mod. Pathol."},{"key":"307_CR90","volume":"2","author":"LH Lee","year":"2017","unstructured":"Lee, L. H. et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight 2, e89473 (2017).","journal-title":"JCI Insight"},{"key":"307_CR91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/DAD.0b013e3181ee547c","volume":"33","author":"E Avitan-Hersh","year":"2011","unstructured":"Avitan-Hersh, E. et al. A case of H syndrome showing immunophenotye similarities to Rosai-Dorfman disease. Am. J. Dermatopathol. 33, 47\u201351 (2011).","journal-title":"Am. J. Dermatopathol."},{"key":"307_CR92","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.20605","volume":"47","author":"HC Rossbach","year":"2006","unstructured":"Rossbach, H. C., Dalence, C., Wynn, T. & Tebbi, C. Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness. Pediatr. Blood Cancer 47, 629\u2013632 (2006).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000833","volume":"6","author":"NV Morgan","year":"2010","unstructured":"Morgan, N. V. et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 6, e1000833 (2010).","journal-title":"PLoS Genet."},{"key":"307_CR94","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.hoc.2015.06.001","volume":"29","author":"J Picarsic","year":"2015","unstructured":"Picarsic, J. & Jaffe, R. Nosology and pathology of Langerhans cell histiocytosis. Hematol. Oncol. Clin. North Am. 29, 799\u2013823 (2015).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"307_CR95","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10875-017-0443-1","volume":"37","author":"S Ammann","year":"2017","unstructured":"Ammann, S. et al. Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis. J. Clin. Immunol. 37, 770\u2013780 (2017).","journal-title":"J. Clin. Immunol."},{"key":"307_CR96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yexcr.2014.03.014","volume":"325","author":"M Meeths","year":"2014","unstructured":"Meeths, M. et al. Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity. Exp. Cell Res. 325, 10\u201317 (2014).","journal-title":"Exp. Cell Res."},{"key":"307_CR97","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","volume":"286","author":"SE Stepp","year":"1999","unstructured":"Stepp, S. E. et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286, 1957\u20131959 (1999).","journal-title":"Science"},{"key":"307_CR98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0092-8674(03)00855-9","volume":"115","author":"J Feldmann","year":"2003","unstructured":"Feldmann, J. et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115, 461\u2013473 (2003).","journal-title":"Cell"},{"key":"307_CR99","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/hmg\/ddi076","volume":"14","author":"SU Zur","year":"2005","unstructured":"Zur, S. U. et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14, 827\u2013834 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"307_CR100","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1172\/JCI40732","volume":"119","author":"M Cote","year":"2009","unstructured":"Cote, M. et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J. Clin. Invest. 119, 3765\u20133773 (2009).","journal-title":"J. Clin. Invest."},{"key":"307_CR101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/76024","volume":"25","author":"G Menasche","year":"2000","unstructured":"Menasche, G. et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25, 173\u2013176 (2000).","journal-title":"Nat. Genet."},{"key":"307_CR102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ng1196-307","volume":"14","author":"DL Nagle","year":"1996","unstructured":"Nagle, D. L. et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat. Genet. 14, 307\u2013311 (1996).","journal-title":"Nat. Genet."},{"key":"307_CR103","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0952-7915(00)00257-0","volume":"13","author":"BG de Saint","year":"2001","unstructured":"de Saint, B. G. & Fischer, A. The role of cytotoxicity in lymphocyte homeostasis. Curr. Opin. Immunol. 13, 549\u2013554 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"307_CR104","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","volume":"78","author":"JI Henter","year":"1991","unstructured":"Henter, J. I. et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78, 2918\u20132922 (1991).","journal-title":"Blood"},{"key":"307_CR105","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V89.11.4100","volume":"89","author":"Y Osugi","year":"1997","unstructured":"Osugi, Y. et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89, 4100\u20134103 (1997).","journal-title":"Blood"},{"key":"307_CR106","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","volume":"72","author":"LA Henderson","year":"2020","unstructured":"Henderson, L. A. et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 72, 1059\u20131063 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"307_CR107","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan, M. B., Hildeman, D., Kappler, J. & Marrack, P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104, 735\u2013743 (2004).","journal-title":"Blood"},{"key":"307_CR108","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/eji.200838488","volume":"38","author":"SJ Pachlopnik","year":"2008","unstructured":"Pachlopnik, S. J. et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur. J. Immunol. 38, 3219\u20133225 (2008).","journal-title":"Eur. J. Immunol."},{"key":"307_CR109","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.20062447","volume":"204","author":"K Crozat","year":"2007","unstructured":"Crozat, K. et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 204, 853\u2013863 (2007).","journal-title":"J. Exp. Med."},{"key":"307_CR110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2012-07-440339","volume":"121","author":"FE Sepulveda","year":"2013","unstructured":"Sepulveda, F. E. et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 121, 595\u2013603 (2013).","journal-title":"Blood"},{"key":"307_CR111","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli, F. et al. Emapalumab in children with Primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med 382, 1811\u20131822 (2020).","journal-title":"N. Engl. J. Med"},{"key":"307_CR112","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/26683","volume":"395","author":"J Sayos","year":"1998","unstructured":"Sayos, J. et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395, 462\u2013469 (1998).","journal-title":"Nature"},{"key":"307_CR113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/2424","volume":"20","author":"AJ Coffey","year":"1998","unstructured":"Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20, 129\u2013135 (1998).","journal-title":"Nat. Genet."},{"key":"307_CR114","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","volume":"95","author":"KE Nichols","year":"1998","unstructured":"Nichols, K. E. et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl Acad. Sci. USA 95, 13765\u201313770 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"307_CR115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature05257","volume":"444","author":"S Rigaud","year":"2006","unstructured":"Rigaud, S. et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444, 110\u2013114 (2006).","journal-title":"Nature"},{"key":"307_CR116","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1172\/JCI37901","volume":"119","author":"K Huck","year":"2009","unstructured":"Huck, K. et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 119, 1350\u20131358 (2009).","journal-title":"J. Clin. Invest."},{"key":"307_CR117","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaci.2011.11.013","volume":"129","author":"JM van Montfrans","year":"2012","unstructured":"van Montfrans, J. M. et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 129, 787\u2013793 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"307_CR118","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature10246","volume":"475","author":"FY Li","year":"2011","unstructured":"Li, F. Y. et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 475, 471\u2013476 (2011).","journal-title":"Nature"},{"key":"307_CR119","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20190147","volume":"216","author":"MT Lam","year":"2019","unstructured":"Lam, M. T. et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J. Exp. Med. 216, 2778\u20132799 (2019).","journal-title":"J. Exp. Med."},{"key":"307_CR120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140\u20131146 (2014).","journal-title":"Nat. Genet."},{"key":"307_CR121","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg, N. et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135\u20131139 (2014).","journal-title":"Nat. Genet."},{"key":"307_CR122","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2014.121608","volume":"100","author":"SF Bode","year":"2015","unstructured":"Bode, S. F. et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica 100, 978\u2013988 (2015).","journal-title":"Haematologica"},{"key":"307_CR123","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2015.07.043","volume":"137","author":"MA Spinner","year":"2016","unstructured":"Spinner, M. A. et al. GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis. J. Allergy Clin. Immunol. 137, 638\u2013640 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"307_CR124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/8904_2018_88","volume":"42","author":"N Althonaian","year":"2018","unstructured":"Althonaian, N., Alsultan, A., Morava, E. & Alfadhel, M. Secondary hemophagocytic syndrome associated with COG6 gene defect: report and review. JIMD Rep. 42, 105\u2013111 (2018).","journal-title":"JIMD Rep."},{"key":"307_CR125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert, G. S. & Grom, A. A. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu. Rev. Med 66, 145\u2013159 (2015).","journal-title":"Annu. Rev. Med"},{"key":"307_CR126","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/adc.75.1.17","volume":"75","author":"The French Langerhans\u2019 Cell Histiocytosis Study Group","year":"1996","unstructured":"The French Langerhans\u2019 Cell Histiocytosis Study Group A multicentre retrospective survey of Langerhans\u2019 cell histiocytosis: 348 cases observed between 1983 and 1993. Arch. Dis. Child. 75, 17\u201324 (1996).","journal-title":"Arch. Dis. Child."},{"key":"307_CR127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","volume":"126","author":"CE Allen","year":"2015","unstructured":"Allen, C. E., Ladisch, S. & McClain, K. L. How I treat Langerhans cell histiocytosis. Blood 126, 26\u201335 (2015).","journal-title":"Blood"},{"key":"307_CR128","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood.2019000934","volume":"135","author":"C Rodriguez-Galindo","year":"2020","unstructured":"Rodriguez-Galindo, C. & Allen, C. E. Langerhans cell histiocytosis. Blood 135, 1319\u20131331 (2020).","journal-title":"Blood"},{"key":"307_CR129","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jpeds.2014.07.063","volume":"165","author":"SJ Simko","year":"2014","unstructured":"Simko, S. J. et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J. Pediatr. 165, 990\u2013996 (2014).","journal-title":"J. Pediatr."},{"key":"307_CR130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cncr.31893","volume":"125","author":"D Chellapandian","year":"2019","unstructured":"Chellapandian, D. et al. A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis. Cancer 125, 963\u2013971 (2019).","journal-title":"Cancer"},{"key":"307_CR131","volume":"65","author":"EA Yeh","year":"2018","unstructured":"Yeh, E. A. et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr. Blood Cancer 65, e26784 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR132","doi-asserted-by":"crossref","first-page":"e2746","DOI":"10.1212\/WNL.0000000000010748","volume":"95","author":"F Cohen-Aubart","year":"2020","unstructured":"Cohen-Aubart, F. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 95, e2746\u2013e2754 (2020).","journal-title":"Neurology"},{"key":"307_CR133","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0022-3476(96)70247-0","volume":"129","author":"DR Freyer","year":"1996","unstructured":"Freyer, D. R., Kennedy, R., Bostrom, B. C., Kohut, G. & Dehner, L. P. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J. Pediatr. 129, 227\u2013237 (1996).","journal-title":"J. Pediatr."},{"key":"307_CR134","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3928\/0191-3913-19910501-10","volume":"28","author":"LM Collum","year":"1991","unstructured":"Collum, L. M., Power, W. J., Mullaney, J. & Farrell, M. Limbal xanthogranuloma. J. Pediatr. Ophthalmol. Strabismus 28, 157\u2013159 (1991).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"307_CR135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1067\/moe.2002.122340","volume":"94","author":"C Flaitz","year":"2002","unstructured":"Flaitz, C., Allen, C., Neville, B. & Hicks, J. Juvenile xanthogranuloma of the oral cavity in children: a clinicopathologic study. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 94, 345\u2013352 (2002).","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod."},{"key":"307_CR136","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","volume":"131","author":"O Abla","year":"2018","unstructured":"Abla, O. et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131, 2877\u20132890 (2018).","journal-title":"Blood"},{"key":"307_CR137","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1016\/j.revmed.2015.03.267","volume":"36","author":"F Cohen-Aubart","year":"2015","unstructured":"Cohen-Aubart, F. et al. La maladie de Rosai-Dorfman-Destombes est une histiocytose inflammatoire polymporphe: etude phenotypique multicentrique de 47 patients [French]. Med. Interne 36, A40\u2013A41 (2015).","journal-title":"Med. Interne"},{"key":"307_CR138","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.5858\/2001-125-1348-RDDOTP","volume":"125","author":"R Juskevicius","year":"2001","unstructured":"Juskevicius, R. & Finley, J. L. Rosai-Dorfman disease of the parotid gland: cytologic and histopathologic findings with immunohistochemical correlation. Arch. Pathol. Lab. Med. 125, 1348\u20131350 (2001).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"307_CR139","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MD.0000000000000030","volume":"93","author":"JD Sandoval-Sus","year":"2014","unstructured":"Sandoval-Sus, J. D. et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore) 93, 165\u2013175 (2014).","journal-title":"Medicine (Baltimore)"},{"key":"307_CR140","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27929","volume":"66","author":"MB Jordan","year":"2019","unstructured":"Jordan, M. B. et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr. Blood Cancer 66, e27929 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR141","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten, E. et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130, 2728\u20132738 (2017).","journal-title":"Blood"},{"key":"307_CR142","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11940-017-0439-4","volume":"19","author":"A Horne","year":"2017","unstructured":"Horne, A. et al. How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr. Treat. Options Neurol. 19, 3 (2017).","journal-title":"Curr. Treat. Options Neurol."},{"key":"307_CR143","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000560","volume":"6","author":"LA Benson","year":"2019","unstructured":"Benson, L. A. et al. Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurol. Neuroimmunol. Neuroinflamm. 6, e560 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"307_CR144","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1086\/345903","volume":"36","author":"DL Palazzi","year":"2003","unstructured":"Palazzi, D. L., McClain, K. L. & Kaplan, S. L. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin. Infect. Dis. 36, 306\u2013312 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"307_CR145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pbc.21782","volume":"52","author":"M Phillips","year":"2009","unstructured":"Phillips, M., Allen, C., Gerson, P. & McClain, K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr. Blood Cancer 52, 97\u2013101 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR146","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28891","volume":"68","author":"J Ferrell","year":"2021","unstructured":"Ferrell, J. et al. Discrepancies between F-18-FDG PET\/CT findings and conventional imaging in Langerhans cell histiocytosis. Pediatr. Blood Cancer 68, e28891 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR147","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.2388","volume":"36","author":"LY Ballester","year":"2018","unstructured":"Ballester, L. Y. et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol. Oncol. 36, 307\u2013315 (2018).","journal-title":"Hematol. Oncol."},{"key":"307_CR148","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00381-003-0874-2","volume":"20","author":"M Tsuji","year":"2004","unstructured":"Tsuji, M. et al. Solitary myofibromatosis of the skull: a case report and review of literature. Childs Nerv. Syst. 20, 366\u2013369 (2004).","journal-title":"Childs Nerv. Syst."},{"key":"307_CR149","first-page":"1848","volume":"87","author":"MR DiCaprio","year":"2005","unstructured":"DiCaprio, M. R. & Enneking, W. F. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J. Bone Jt. Surg. Am. 87, 1848\u20131864 (2005).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"307_CR150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-3476(86)80581-9","volume":"109","author":"R Adler","year":"1986","unstructured":"Adler, R. & Wong, C. A. Cranial fasciitis simulating histiocytosis. J. Pediatr. 109, 85\u201388 (1986).","journal-title":"J. Pediatr."},{"key":"307_CR151","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal, G. et al. Erdheim-Chester disease: consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood 135, 1929\u20131945 (2020).","journal-title":"Blood"},{"key":"307_CR152","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/art.24848","volume":"60","author":"L Arnaud","year":"2009","unstructured":"Arnaud, L. et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 60, 3128\u20133138 (2009).","journal-title":"Arthritis Rheum."},{"key":"307_CR153","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond, E. L. et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124, 483\u2013492 (2014).","journal-title":"Blood"},{"key":"307_CR154","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","volume":"119","author":"J Haroche","year":"2009","unstructured":"Haroche, J. et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 119, e597\u2013e598 (2009).","journal-title":"Circulation"},{"key":"307_CR155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.md.0000145368.17934.91","volume":"83","author":"J Haroche","year":"2004","unstructured":"Haroche, J. et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 83, 371\u2013392 (2004).","journal-title":"Medicine (Baltimore)"},{"key":"307_CR156","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa, T., Zen, Y., Pillai, S. & Stone, J. H. IgG4-related disease. Lancet 385, 1460\u20131471 (2015).","journal-title":"Lancet"},{"key":"307_CR157","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/archderm.1975.01630150085012","volume":"111","author":"P Morier","year":"1975","unstructured":"Morier, P. et al. Juvenile xanthogranuloma and urticaria pigmentosa. Arch. Dermatol. 111, 365\u2013366 (1975).","journal-title":"Arch. Dermatol."},{"key":"307_CR158","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.pas.0000157997.61177.08","volume":"29","author":"I Maric","year":"2005","unstructured":"Maric, I. et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am. J. Surg. Pathol. 29, 903\u2013911 (2005).","journal-title":"Am. J. Surg. Pathol."},{"key":"307_CR159","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pbc.25017","volume":"61","author":"SR Vaiselbuh","year":"2014","unstructured":"Vaiselbuh, S. R., Bryceson, Y. T., Allen, C. E., Whitlock, J. A. & Abla, O. Updates on histiocytic disorders. Pediatr. Blood Cancer 61, 1329\u20131335 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR160","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1309\/AJCPARC3YQ0KLIOA","volume":"139","author":"X Zhang","year":"2013","unstructured":"Zhang, X., Hyjek, E. & Vardiman, J. A subset of Rosai-Dorfman disease exhibits features of IgG4-related disease. Am. J. Clin. Pathol. 139, 622\u2013632 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"307_CR161","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/pbc.21564","volume":"51","author":"A Gupta","year":"2008","unstructured":"Gupta, A. et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 51, 402\u2013404 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR162","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPMD5TJEFOOVBW","volume":"141","author":"C Ho","year":"2014","unstructured":"Ho, C. et al. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am. J. Clin. Pathol. 141, 62\u201371 (2014).","journal-title":"Am. J. Clin. Pathol."},{"key":"307_CR163","first-page":"21","volume":"42","author":"S Goel","year":"2012","unstructured":"Goel, S., Polski, J. M. & Imran, H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann. Clin. Lab Sci. 42, 21\u201325 (2012).","journal-title":"Ann. Clin. Lab Sci."},{"key":"307_CR164","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/pbc.25058","volume":"61","author":"K Lehmberg","year":"2014","unstructured":"Lehmberg, K., McClain, K. L., Janka, G. E. & Allen, C. E. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 61, 2101\u20132103 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR165","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","volume":"1","author":"A Hayden","year":"2017","unstructured":"Hayden, A. et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 1, 2529\u20132534 (2017).","journal-title":"Blood Adv."},{"key":"307_CR166","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson, Y. T., March, M. E., Ljunggren, H. G. & Long, E. O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107, 159\u2013166 (2006).","journal-title":"Blood"},{"key":"307_CR167","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2016-12-753830","volume":"129","author":"TS Rubin","year":"2017","unstructured":"Rubin, T. S. et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood 129, 2993\u20132999 (2017).","journal-title":"Blood"},{"key":"307_CR168","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss, E. S. et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 131, 1442\u20131455 (2018).","journal-title":"Blood"},{"key":"307_CR169","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2021004287","volume":"5","author":"H Lin","year":"2021","unstructured":"Lin, H. et al. IFN-\u03b3 signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 5, 3457\u20133467 (2021).","journal-title":"Blood Adv."},{"key":"307_CR170","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","volume":"127","author":"S Riviere","year":"2014","unstructured":"Riviere, S. et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am. J. Med. 127, 1118\u20131125 (2014).","journal-title":"Am. J. Med."},{"key":"307_CR171","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","volume":"89","author":"SA Parikh","year":"2014","unstructured":"Parikh, S. A., Kapoor, P., Letendre, L., Kumar, S. & Wolanskyj, A. P. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin. Proc. 89, 484\u2013492 (2014).","journal-title":"Mayo Clin. Proc."},{"key":"307_CR172","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","volume":"123","author":"N Daver","year":"2017","unstructured":"Daver, N. et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123, 3229\u20133240 (2017).","journal-title":"Cancer"},{"key":"307_CR173","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","volume":"170","author":"K Lehmberg","year":"2015","unstructured":"Lehmberg, K. et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br. J. Haematol. 170, 539\u2013549 (2015).","journal-title":"Br. J. Haematol."},{"key":"307_CR174","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2015-06-648659","volume":"126","author":"M Abdalgani","year":"2015","unstructured":"Abdalgani, M. et al. Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations. Blood 126, 1858\u20131860 (2015).","journal-title":"Blood"},{"key":"307_CR175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cytob.21166","volume":"86","author":"CE Gifford","year":"2014","unstructured":"Gifford, C. E. et al. Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP\/BIRC4 mutations. Cytom. B Clin. Cytom. 86, 263\u2013271 (2014).","journal-title":"Cytom. B Clin. Cytom."},{"key":"307_CR176","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.12306","volume":"176","author":"S Ammann","year":"2014","unstructured":"Ammann, S. et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin. Exp. Immunol. 176, 394\u2013400 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"307_CR177","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood-2011-08-374199","volume":"119","author":"YT Bryceson","year":"2012","unstructured":"Bryceson, Y. T. et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119, 2754\u20132763 (2012).","journal-title":"Blood"},{"key":"307_CR178","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/ACI.0000000000000396","volume":"17","author":"N Romberg","year":"2017","unstructured":"Romberg, N., Vogel, T. P. & Canna, S. W. NLRC4 inflammasomopathies. Curr. Opin. Allergy Clin. Immunol. 17, 398\u2013404 (2017).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"307_CR179","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2013.09.007","volume":"65","author":"T Wada","year":"2014","unstructured":"Wada, T. et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 65, 74\u201378 (2014).","journal-title":"Cytokine"},{"key":"307_CR180","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/bloodadvances.2020001605","volume":"4","author":"V Gadoury-Levesque","year":"2020","unstructured":"Gadoury-Levesque, V. et al. Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders. Blood Adv. 4, 2578\u20132594 (2020).","journal-title":"Blood Adv."},{"key":"307_CR181","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli, A. et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 75, 481\u2013489 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"307_CR182","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10024-004-3027-z","volume":"7","author":"K Chikwava","year":"2004","unstructured":"Chikwava, K. & Jaffe, R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr. Dev. Pathol. 7, 607\u2013614 (2004).","journal-title":"Pediatr. Dev. Pathol."},{"key":"307_CR183","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2350\/15-01-1593-OA.1","volume":"18","author":"J Picarsic","year":"2015","unstructured":"Picarsic, J., Egeler, R. M., Chikwava, K., Patterson, K. & Jaffe, R. Histologic patterns of thymic involvement in Langerhans cell proliferations: a clinicopathologic study and review of the literature. Pediatr. Dev. Pathol. 18, 127\u2013138 (2015).","journal-title":"Pediatr. Dev. Pathol."},{"key":"307_CR184","doi-asserted-by":"crossref","unstructured":"Picarsic, J. & Jaffe, R. in Histiocytic Disorders (eds Abla, O. & Janka, G.) 3\u201350 (Springer, 2018).","DOI":"10.1007\/978-3-319-59632-7_1"},{"key":"307_CR185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000372-199610000-00008","volume":"18","author":"BW Zelger","year":"1996","unstructured":"Zelger, B. W., Sidoroff, A., Orchard, G. & Cerio, R. Non-Langerhans cell histiocytoses. A new unifying concept. Am. J. Dermatopathol. 18, 490\u2013504 (1996).","journal-title":"Am. J. Dermatopathol."},{"key":"307_CR186","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0046-8177(92)90320-3","volume":"23","author":"M Paulli","year":"1992","unstructured":"Paulli, M. et al. Immunophenotypic characterization of the cell infiltrate in five cases of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Hum. Pathol. 23, 647\u2013654 (1992).","journal-title":"Hum. Pathol."},{"key":"307_CR187","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2559.1998.00377.x","volume":"32","author":"A Ost","year":"1998","unstructured":"Ost, A., Nilsson-Ardnor, S. & Henter, J. I. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology 32, 310\u2013316 (1998).","journal-title":"Histopathology"},{"key":"307_CR188","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond, E. L. et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 567, 521\u2013524 (2019).","journal-title":"Nature"},{"key":"307_CR189","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","volume":"130","author":"AF Cohen","year":"2017","unstructured":"Cohen, A. F. et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130, 1377\u20131380 (2017).","journal-title":"Blood"},{"key":"307_CR190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/01241398-199211000-00021","volume":"12","author":"RM Egeler","year":"1992","unstructured":"Egeler, R. M., Thompson, R. C. Jr., Voute, P. A. & Nesbit, M. E. Jr. Intralesional infiltration of corticosteroids in localized Langerhans\u2019 cell histiocytosis. J. Pediatr. Orthop. 12, 811\u2013814 (1992).","journal-title":"J. Pediatr. Orthop."},{"key":"307_CR191","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1164\/ajrccm.157.6.9709026","volume":"157","author":"A Tazi","year":"1998","unstructured":"Tazi, A. et al. Relapsing nodular lesions in the course of adult pulmonary Langerhans cell histiocytosis. Am. J. Respir. Crit. Care Med. 157, 2007\u20132010 (1998).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"307_CR192","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ppul.24822","volume":"55","author":"OS Eckstein","year":"2020","unstructured":"Eckstein, O. S. et al. Management of severe pulmonary Langerhans cell histiocytosis in children. Pediatr. Pulmonol. 55, 2074\u20132081 (2020).","journal-title":"Pediatr. Pulmonol."},{"key":"307_CR193","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood-2016-06-721993","volume":"128","author":"DJ Zinn","year":"2016","unstructured":"Zinn, D. J. et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood 128, 2462\u20132465 (2016).","journal-title":"Blood"},{"key":"307_CR194","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2000-9667","volume":"212","author":"M Minkov","year":"2000","unstructured":"Minkov, M. et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. Klin. Padiatr. 212, 139\u2013144 (2000).","journal-title":"Klin. Padiatr."},{"key":"307_CR195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pbc.20578","volume":"48","author":"KL McClain","year":"2007","unstructured":"McClain, K. L. & Kozinetz, C. A. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr. Blood Cancer 48, 44\u201349 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR196","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpeds.2003.12.030","volume":"144","author":"J Donadieu","year":"2004","unstructured":"Donadieu, J. et al. Endocrine involvement in pediatric-onset Langerhans\u2019 cell histiocytosis: a population-based study. J. Pediatr. 144, 344\u2013350 (2004).","journal-title":"J. Pediatr."},{"key":"307_CR197","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bjh.13208","volume":"169","author":"SJ Simko","year":"2015","unstructured":"Simko, S. J., McClain, K. L. & Allen, C. E. Up-front therapy for LCH: is it time to test an alternative to vinblastine\/prednisone? Br. J. Haematol. 169, 299\u2013301 (2015).","journal-title":"Br. J. Haematol."},{"key":"307_CR198","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/pbc.22229","volume":"53","author":"S Weitzman","year":"2009","unstructured":"Weitzman, S. et al. 2\u2032-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr. Blood Cancer 53, 1271\u20131276 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR199","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/pbc.22326","volume":"54","author":"CE Allen","year":"2010","unstructured":"Allen, C. E. et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine\/cytosine arabinoside. Pediatr. Blood Cancer 54, 416\u2013423 (2010).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","volume":"104","author":"A Morimoto","year":"2016","unstructured":"Morimoto, A. et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int. J. Hematol. 104, 99\u2013109 (2016).","journal-title":"Int. J. Hematol."},{"key":"307_CR201","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.24772","volume":"61","author":"SJ Simko","year":"2014","unstructured":"Simko, S. J. et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr. Blood Cancer 61, 479\u2013487 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR202","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.26119","volume":"96","author":"G Goyal","year":"2021","unstructured":"Goyal, G. et al. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am. J. Hematol. 96, E146\u2013E150 (2021).","journal-title":"Am. J. Hematol."},{"key":"307_CR203","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lpm.2016.09.016","volume":"46","author":"G Lorillon","year":"2017","unstructured":"Lorillon, G., Meignin, V. & Tazi, A. Adult pulmonary Langerhans cell histiocytosis [French]. Presse Med. 46, 70\u201378 (2017).","journal-title":"Presse Med."},{"key":"307_CR204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043257","volume":"7","author":"MA Cantu","year":"2012","unstructured":"Cantu, M. A. et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS ONE 7, e43257 (2012).","journal-title":"PLoS ONE"},{"key":"307_CR205","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0651-z","volume":"12","author":"A Tazi","year":"2017","unstructured":"Tazi, A. et al. Vinblastine chemotherapy in adult patients with Langerhans cell histiocytosis: a multicenter retrospective study. Orphanet. J. Rare. Dis. 12, 95 (2017).","journal-title":"Orphanet. J. Rare. Dis."},{"key":"307_CR206","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1903-8","volume":"15","author":"E Derenzini","year":"2015","unstructured":"Derenzini, E. et al. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. BMC Cancer 15, 879 (2015).","journal-title":"BMC Cancer"},{"key":"307_CR207","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s12185-011-0839-2","volume":"93","author":"S Sivendran","year":"2011","unstructured":"Sivendran, S., Harvey, H., Lipton, A. & Drabick, J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int. J. Hematol. 93, 782\u2013786 (2011).","journal-title":"Int. J. Hematol."},{"key":"307_CR208","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjh.16944","volume":"191","author":"MA Barkaoui","year":"2020","unstructured":"Barkaoui, M. A. et al. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br. J. Haematol. 191, 825\u2013834 (2020).","journal-title":"Br. J. Haematol."},{"key":"307_CR209","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","volume":"126","author":"J Donadieu","year":"2015","unstructured":"Donadieu, J. et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood 126, 1415\u20131423 (2015).","journal-title":"Blood"},{"key":"307_CR210","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond, E. L. et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 4, 384\u2013388 (2018).","journal-title":"JAMA Oncol."},{"key":"307_CR211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726\u2013736 (2015).","journal-title":"N. Engl. J. Med."},{"key":"307_CR212","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud, L. et al. CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 117, 2778\u20132782 (2011).","journal-title":"Blood"},{"key":"307_CR213","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche, J. et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121, 1495\u20131500 (2013).","journal-title":"Blood"},{"key":"307_CR214","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","volume":"127","author":"F Cohen-Aubart","year":"2016","unstructured":"Cohen-Aubart, F. et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood 127, 1509\u20131512 (2016).","journal-title":"Blood"},{"key":"307_CR215","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/annrheumdis-2017-212678","volume":"77","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart, F. et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann. Rheum. Dis. 77, 1387\u20131390 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"307_CR216","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.2019004478","volume":"135","author":"F Pegoraro","year":"2020","unstructured":"Pegoraro, F. et al. Long-term follow-up of mTOR inhibition for Erdheim-Chester disease. Blood 135, 1994\u20131997 (2020).","journal-title":"Blood"},{"key":"307_CR217","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/MPA.0000000000001704","volume":"50","author":"GJ Ruan","year":"2021","unstructured":"Ruan, G. J. et al. Acute pancreatitis from treatment with BRAF inhibitors in Erdheim-Chester disease: a report from 2 tertiary referral centers. Pancreas 50, e6\u2013e8 (2021).","journal-title":"Pancreas"},{"key":"307_CR218","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras, J. I. et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 1, 357\u2013366 (2017).","journal-title":"Blood Adv."},{"key":"307_CR219","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","volume":"180","author":"AF Cohen","year":"2018","unstructured":"Cohen, A. F. et al. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. Br. J. Haematol. 180, 150\u2013153 (2018).","journal-title":"Br. J. Haematol."},{"key":"307_CR220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.21523","volume":"51","author":"DG Stover","year":"2008","unstructured":"Stover, D. G., Alapati, S., Regueira, O., Turner, C. & Whitlock, J. A. Treatment of juvenile xanthogranuloma. Pediatr. Blood Cancer 51, 130\u2013133 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR221","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pbc.22629","volume":"55","author":"P Blouin","year":"2010","unstructured":"Blouin, P. et al. Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC. Pediatr. Blood Cancer 55, 757\u2013760 (2010).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR222","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.10008","volume":"69","author":"A Pulsoni","year":"2002","unstructured":"Pulsoni, A. et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am. J. Hematol. 69, 67\u201371 (2002).","journal-title":"Am. J. Hematol."},{"key":"307_CR223","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-911X(199609)27:3<187::AID-MPO10>3.0.CO;2-D","volume":"27","author":"G Horneff","year":"1996","unstructured":"Horneff, G., Jurgens, H., Hort, W., Karitzky, D. & Gobel, U. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Med. Pediatr. Oncol. 27, 187\u2013192 (1996).","journal-title":"Med. Pediatr. Oncol."},{"key":"307_CR224","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0190-9622(97)70186-5","volume":"37","author":"MM Scheel","year":"1997","unstructured":"Scheel, M. M., Rady, P. L., Tyring, S. K. & Pandya, A. G. Sinus histiocytosis with massive lymphadenopathy: presentation as giant granuloma annulare and detection of human herpesvirus 6. J. Am. Acad. Dermatol. 37, 643\u2013646 (1997).","journal-title":"J. Am. Acad. Dermatol."},{"key":"307_CR225","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1200\/JCO.1997.15.5.2176","volume":"15","author":"L Palomera","year":"1997","unstructured":"Palomera, L., Domingo, J. M., Olave, T., Romero, S. & Gutierrez, M. Sinus histiocytosis with massive lymphadenopathy: complete response to low-dose interferon-alpha. J. Clin. Oncol. 15, 2176 (1997).","journal-title":"J. Clin. Oncol."},{"key":"307_CR226","first-page":"179","volume":"85","author":"EM Baildam","year":"1992","unstructured":"Baildam, E. M., Ewing, C. I., D\u2019Souza, S. W. & Stevens, R. F. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to acyclovir. J. R. Soc. Med. 85, 179\u2013180 (1992).","journal-title":"J. R. Soc. Med."},{"key":"307_CR227","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jdcr.2016.08.006","volume":"2","author":"E Chen","year":"2016","unstructured":"Chen, E., Pavlidakey, P. & Sami, N. Rosai-Dorfman disease successfully treated with thalidomide. JAAD Case. Rep. 2, 369\u2013372 (2016).","journal-title":"JAAD Case. Rep."},{"key":"307_CR228","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/archderm.143.6.736","volume":"143","author":"J Utikal","year":"2007","unstructured":"Utikal, J. et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch. Dermatol. 143, 736\u2013740 (2007).","journal-title":"Arch. Dermatol."},{"key":"307_CR229","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00043426-200401000-00007","volume":"26","author":"C Rodriguez-Galindo","year":"2004","unstructured":"Rodriguez-Galindo, C. et al. Extranodal Rosai-Dorfman disease in children. J. Pediatr. Hematol. Oncol. 26, 19\u201324 (2004).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"307_CR230","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/10428194.2019.1703971","volume":"61","author":"EC Namoglu","year":"2020","unstructured":"Namoglu, E. C. et al. Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease). Leuk. Lymphoma 61, 905\u2013911 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"307_CR231","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.09.036","volume":"157","author":"Q Moyon","year":"2020","unstructured":"Moyon, Q. et al. Lung involvement in Destombes-Rosai-Dorfman disease: clinical and radiological features and response to the MEK inhibitor cobimetinib. Chest 157, 323\u2013333 (2020).","journal-title":"Chest"},{"key":"307_CR232","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl, S. et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the Histiocyte Society. J. Allergy Clin. Immunol. Pract. 6, 1508\u20131517 (2018).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"307_CR233","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","volume":"192","author":"TS Johnson","year":"2014","unstructured":"Johnson, T. S. et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J. Immunol. 192, 84\u201391 (2014).","journal-title":"J. Immunol."},{"key":"307_CR234","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1542\/peds.2006-3164","volume":"120","author":"N Mahlaoui","year":"2007","unstructured":"Mahlaoui, N. et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120, e622\u2013e628 (2007).","journal-title":"Pediatrics"},{"key":"307_CR235","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter, J. I. et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100, 2367\u20132373 (2002).","journal-title":"Blood"},{"key":"307_CR236","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bjh.12386","volume":"162","author":"D Chellapandian","year":"2013","unstructured":"Chellapandian, D. et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br. J. Haematol. 162, 376\u2013382 (2013).","journal-title":"Br. J. Haematol."},{"key":"307_CR237","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli, A., Grom, A. A., Behrens, E. M. & Cron, R. Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13, 289\u2013298 (2012).","journal-title":"Genes Immun."},{"key":"307_CR238","volume":"68","author":"S Ehl","year":"2021","unstructured":"Ehl, S. et al. Is neutralization of IFN-\u03b3 sufficient to control inflammation in HLH? Pediatr. Blood Cancer 68, e28886 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR239","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrclinonc.2010.40","volume":"7","author":"MP Strout","year":"2010","unstructured":"Strout, M. P., Seropian, S. & Berliner, N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat. Rev. Clin. Oncol. 7, 415\u2013420 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"307_CR240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh, R. A. et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr. Blood Cancer 60, 101\u2013109 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR241","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das, R. et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127, 1666\u20131675 (2016).","journal-title":"Blood"},{"key":"307_CR242","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi, S., Sepulveda, F. E., Garrigue, A., Fischer, A. & de Saint, B. G. Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128, 60\u201371 (2016).","journal-title":"Blood"},{"key":"307_CR243","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","volume":"12","author":"JH Sin","year":"2019","unstructured":"Sin, J. H. & Zangardi, M. L. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol. Oncol. Stem Cell Ther. 12, 166\u2013170 (2019).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"307_CR244","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"L Broglie","year":"2017","unstructured":"Broglie, L. et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 1, 1533\u20131536 (2017).","journal-title":"Blood Adv."},{"key":"307_CR245","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed, A. et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 6, e630\u2013e637 (2019).","journal-title":"Lancet Haematol."},{"key":"307_CR246","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily, E. M. et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72, 326\u2013334 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"307_CR247","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay, C. et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann. Rheum. Dis. 77, 840\u2013847 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"307_CR248","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","volume":"132","author":"CE Allen","year":"2018","unstructured":"Allen, C. E. et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood 132, 1438\u20131451 (2018).","journal-title":"Blood"},{"key":"307_CR249","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2015-12-684498","volume":"127","author":"B Hartz","year":"2016","unstructured":"Hartz, B. et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood 127, 3281\u20133290 (2016).","journal-title":"Blood"},{"key":"307_CR250","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","volume":"4","author":"M Felber","year":"2020","unstructured":"Felber, M. et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 4, 1998\u20132010 (2020).","journal-title":"Blood Adv."},{"key":"307_CR251","first-page":"e84","volume":"188","author":"SH Naik","year":"2020","unstructured":"Naik, S. H. et al. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br. J. Haematol. 188, e84\u2013e87 (2020).","journal-title":"Br. J. Haematol."},{"key":"307_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.031","author":"RA Marsh","year":"2021","unstructured":"Marsh, R. A. et al. A comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.031 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"307_CR253","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pbc.20021","volume":"42","author":"R Haupt","year":"2004","unstructured":"Haupt, R. et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society\u2013Late Effects Study Group. Pediatr. Blood Cancer 42, 438\u2013444 (2004).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR254","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.ejca.2006.05.031","volume":"42","author":"VR Nanduri","year":"2006","unstructured":"Nanduri, V. R., Pritchard, J., Levitt, G. & Glaser, A. W. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur. J. Cancer 42, 2563\u20132569 (2006).","journal-title":"Eur. J. Cancer"},{"key":"307_CR255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/pbc.21740","volume":"52","author":"CM Vrijmoet-Wiersma","year":"2009","unstructured":"Vrijmoet-Wiersma, C. M. et al. Health-related quality of life, cognitive functioning and behaviour problems in children with Langerhans cell histiocytosis. Pediatr. Blood Cancer 52, 116\u2013122 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR256","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246604","volume":"16","author":"E Bugnet","year":"2021","unstructured":"Bugnet, E. et al. Psychological features of adult patients with langerhans cell histiocytosis. PLoS ONE 16, e0246604 (2021).","journal-title":"PLoS ONE"},{"key":"307_CR257","first-page":"821","volume":"17","author":"S Mammano","year":"1997","unstructured":"Mammano, S., Candiotto, S. & Balsano, M. Cast and brace treatment of eosinophilic granuloma of the spine: long-term follow-up. J. Pediatr. Orthop. 17, 821\u2013827 (1997).","journal-title":"J. Pediatr. Orthop."},{"key":"307_CR258","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpeds.2011.12.035","volume":"161","author":"L Ronceray","year":"2012","unstructured":"Ronceray, L., Potschger, U., Janka, G., Gadner, H. & Minkov, M. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J. Pediatr. 161, 129\u2013133 (2012).","journal-title":"J. Pediatr."},{"key":"307_CR259","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1183\/09031936.96.09102002","volume":"9","author":"A Delobbe","year":"1996","unstructured":"Delobbe, A., Durieu, J., Duhamel, A. & Wallaert, B. Determinants of survival in pulmonary Langerhans\u2019 cell granulomatosis (histiocytosis X). Groupe d\u2019Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur. Respir. J. 9, 2002\u20132006 (1996).","journal-title":"Eur. Respir. J."},{"key":"307_CR260","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mpo.10064","volume":"39","author":"KL McClain","year":"2002","unstructured":"McClain, K. L., Gonzalez, J. M., Jonkers, R., De, J. E. & Egeler, M. Need for a cooperative study: pulmonary Langerhans cell histiocytosis and its management in adults. Med. Pediatr. Oncol. 39, 35\u201339 (2002).","journal-title":"Med. Pediatr. Oncol."},{"key":"307_CR261","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/088800199276921","volume":"16","author":"J Braier","year":"1999","unstructured":"Braier, J. et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr. Hematol. Oncol. 16, 377\u2013385 (1999).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"307_CR262","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/bloodadvances.2018030502","volume":"3","author":"EL Diamond","year":"2019","unstructured":"Diamond, E. L. et al. A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Adv. 3, 934\u2013938 (2019).","journal-title":"Blood Adv."},{"key":"307_CR263","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28381","volume":"67","author":"M Maeda","year":"2020","unstructured":"Maeda, M. et al. Long-term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan. Pediatr. Blood Cancer 67, e28381 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"307_CR264","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jaci.2018.08.010","volume":"142","author":"RA Marsh","year":"2018","unstructured":"Marsh, R. A. et al. Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. J. Allergy Clin. Immunol. 142, 2004\u20132007 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"307_CR265","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1541-7786.MCR-17-0433","volume":"16","author":"V Peyret","year":"2018","unstructured":"Peyret, V. et al. Functional toll-like receptor 4 overexpression in papillary thyroid cancer by MAPK\/ERK-induced ETS1 transcriptional activity. Mol. Cancer Res. 16, 833\u2013845 (2018).","journal-title":"Mol. Cancer Res."},{"key":"307_CR266","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.05.002","volume":"153","author":"M Minkov","year":"2008","unstructured":"Minkov, M. et al. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J. Pediatr. 153, 700\u2013705 (2008).","journal-title":"J. Pediatr."},{"key":"307_CR267","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/mpo.2950210406","volume":"21","author":"RM Egeler","year":"1993","unstructured":"Egeler, R. M., de, K. J. & Voute, P. A. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med. Pediatr. Oncol. 21, 265\u2013270 (1993).","journal-title":"Med. Pediatr. Oncol."},{"key":"307_CR268","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. & Marsh, R. A. Pediatric hemophagocytic lymphohistiocytosis. Blood 135, 1332\u20131343 (2020).","journal-title":"Blood"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00307-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T08:51:05Z","timestamp":1725871865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-021-00307-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":268,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1038\/s41572-021-00307-9","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"7 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.M. and C.E.A. have served on advisory committees for SOBI Corporation. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}